Back to Trades
Sell4
Keros Therapeutics, Inc.
KROS
Total Value
$95.7M
Net $95.7M sold
Sales
$95.7M
3 transactions
Company Information
- Company Name
- Keros Therapeutics, Inc.
- Ticker Symbol
- KROS
- CIK
- 0001664710
Insider Information
- Role
- 10% Owner
- Location
- AUSTIN, TX
10% Owner
Filing Details
- Filing Date
- Oct 15, 2025
- Transaction Date
- Oct 15, 2025
- Accession Number
- 0000902664-25-004411
- Form Type
- 4
- Net Trading Amount
- -$95.7M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Oct 15, 2025 | Common Stock | 4,391,237 | $17.75 | Sale | $77.9M |
| Oct 15, 2025 | Common Stock | 254,669 | $17.75 | Sale | $4.5M |
| Oct 15, 2025 | Common Stock | 743,358 | $17.75 | Sale | $13.2M |
Footnotes
- (F1)The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP.
- (F2)For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.